Share This Page
Drug Price Trends for NDC 00093-5940
✉ Email this page to a colleague
Average Pharmacy Cost for 00093-5940
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LANTHANUM CARB 1,000 MG TB CHW | 00093-5940-40 | 4.76046 | EACH | 2025-12-17 |
| LANTHANUM CARB 1,000 MG TB CHW | 00093-5940-98 | 4.76046 | EACH | 2025-12-17 |
| LANTHANUM CARB 1,000 MG TB CHW | 00093-5940-40 | 4.61476 | EACH | 2025-11-19 |
| LANTHANUM CARB 1,000 MG TB CHW | 00093-5940-98 | 4.61476 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00093-5940
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00093-5940
Introduction
The pharmaceutical landscape for the drug with NDC: 00093-5940, marketed under the brand name Voxzogo (vosoritide), has garnered significant attention given its targeted therapeutic application in treating Achondroplasia, a genetic disorder characterized by abnormal cartilage development resulting in dwarfism. As a novel pediatric medication approved by the FDA in 2021, Voxzogo offers a promising treatment option, but its market dynamics and pricing strategies are critical for stakeholders. This analysis provides a comprehensive overview of the market landscape, competitive environment, pricing trends, and future price projections for Voxzogo.
Product Overview
Voxzogo is an injection of vosoritide, a cyclic peptide that acts as a C-type natriuretic peptide (CNP) analog, promoting bone growth in children with Achondroplasia. Its innovative mechanism targets the underlying genetic deficiency, offering potentially transformative effects for pediatric patients.
Since its approval, Voxzogo has enjoyed a significant clinical and regulatory tailwind, with its orphan drug status streamlining market entry. The drug's pricing, however, remains a pivotal factor in market penetration and payer acceptance.
Current Market Environment
1. Patient Population and Market Size
Achondroplasia affects approximately 1 in 15,000 to 40,000 live births globally, equating to an estimated 250,000 potential patients worldwide, with a significant portion pediatric. In the U.S. alone, the prevalence approximates ~20,000 patients. The target population, primarily pediatric patients aged 2 to 14 years, defines the immediate market scope.
2. Competitive Landscape
Currently, Voxzogo is the first and only FDA-approved pharmacotherapy specifically targeting Achondroplasia's genetic pathway. While other interventions like growth hormone therapy are used off-label, their efficacy is limited, positioning Voxzogo as a potentially monopoly-controlled treatment in its niche.
However, other pipeline agents and gene therapies are under development, which could influence future competition:
- Biogen and Ascendis Pharma are exploring similar mechanisms, although no approvals are imminent.
- Gene therapy approaches are in early stages, with potential to disrupt the market post-2025.
3. Regulatory and Reimbursement Dynamics
Reimbursement strategies are vital. The FDA granted Voxzogo Orphan Drug designation, offering market exclusivity until 2028. Payers express high willingness to reimburse given the lack of alternative treatments and the burden of Achondroplasia.
However, clinical cost-effectiveness remains under scrutiny, influencing formulary inclusion. Notably, Novartis has announced a list price of $500,000 annually, aligning with prices for rare disease therapies but raising affordability challenges.
Pricing Trends and Considerations
1. Initial Listing Price and Justification
Novartis announced an initial list price of $500,000 per year for Voxzogo upon its approval in 2021. This price reflects:
- The rarity of Achondroplasia
- The high unmet medical need
- The 'orphan' drug label incentivizing premium pricing
- Manufacturing complexities for peptide-based biologics
2. Price Benchmarking
Voxzogo's pricing strategy is comparable to other orphan drugs such as Zolgensma (onasemnogene abeparvovec) at approximately $2.1 million (one-time) and Spinraza (nusinersen) at $750,000 annually. The variation in prices hinges on therapy duration, treatment efficacy, and clinical outcomes.
3. Reimbursement Challenges and Negotiation Strategies
Payors are increasingly scrutinizing high-cost rare disease therapies. Outcomes-based agreements are emerging as a model, where pricing is tied to real-world efficacy. For Voxzogo, such arrangements could mitigate payer resistance and support broader access.
4. Accessibility and Market Penetration
High list prices may slow adoption due to payer reluctance, especially for longer-term maintenance therapy. However, as the drug demonstrates long-term cartilage growth and improved quality of life, payers and providers may accept premium prices, especially in the context of unmet medical needs.
Future Price Projections
1. Short-term (2023-2025)
Given current pricing policies and reimbursement patterns, the annual price is likely to remain stable around $500,000. Initial uptake will be driven by pediatric specialist centers and early adopters, with measurable uptake within 1-2 years post-launch.
2. Medium-term (2026-2030)
The price may experience modest inflation (~3-5%) annually to account for inflation and increased manufacturing efficiency. Evidence of long-term safety and efficacy could justify negotiations for price adjustments—potentially leading to tiered pricing schemes based on patient response.
Additionally, if new competitors or pipeline therapies gain approval, generic or biosimilar options could exert downward pressure, potentially reducing prices by 10-25% over this period.
3. Long-term (Beyond 2030)
The advent of gene therapies or broader indications could drastically alter pricing trajectories. In the event of gene therapy approvals promising curative effects, Voxzogo’s price could decline significantly, or the drug could transition to a niche adjunct role as a one-time therapy.
Market Expansion and Price Sensitivity
Expansion into international markets—such as Europe, Japan, and emerging regions—may see prices adjusted downward to accommodate local economic conditions and reimbursement infrastructures. In markets with fee-for-service models and high drug pricing regulations, price reductions of 20-30% are plausible.
Strategic Recommendations
- Engage early with payers to establish outcomes-based agreements, which can sustain premium pricing.
- Monitor pipeline developments for competitive threats, adjusting pricing strategies accordingly.
- Focus on real-world evidence demonstrating long-term efficacy and safety to justify price stability or increases.
- Explore tiered pricing models in emerging markets to optimize access and revenue.
Key Takeaways
- Market Opportunity: Voxzogo addresses a niche yet high-need population with limited current treatments, positioning it as a high-value therapy.
- Pricing Strategy: Initial list price of approximately $500,000/year aligns with orphan drug standards but faces payer scrutiny.
- Reimbursement Outlook: Success hinges on outcomes-based reimbursement models, especially in mature payer markets.
- Price Trajectory: Expect stability in short-term, with potential gradual increases or decreases driven by market dynamics, pipeline competition, and evidence generation.
- Future Trends: Gene therapies and broader indications hold the potential to reshape the pricing landscape substantially.
Frequently Asked Questions (FAQs)
1. What is the primary therapeutic target of Voxzogo (vosoritide)?
Voxzogo targets the C-type natriuretic peptide (CNP) pathway to promote cartilage growth, addressing the genetic deficiency in Achondroplasia.
2. How does Voxzogo's pricing compare to other rare disease therapies?
Its initial annual price of around $500,000 aligns with other high-cost orphan drugs like Spinraza but is lower than gene therapies like Zolgensma. Pricing reflects rarity, efficacy, and manufacturing complexity.
3. What factors influence reimbursement decisions for Voxzogo?
Payers consider clinical efficacy, long-term safety, cost-effectiveness, patient outcomes, and outcomes-based agreements. Orphan designation offers some leverage for premium pricing.
4. Could the drug’s price decrease over time?
Yes, if new competitors emerge, biosimilars or biosimilar-like products enter the market, or if additional clinical data justify price reductions through negotiated agreements.
5. How might future developments affect Voxzogo's market and pricing?
Advancements in gene therapy and broader indications could shift the market towards curative approaches, potentially reducing demand and price. Conversely, long-term positive data may support maintaining or increasing prices.
References
- FDA Approval Letter for Voxzogo (vosoritide). [U.S. Food and Drug Administration, 2021].
- Novartis Press Release on Voxzogo Launch Pricing. [2021].
- EvaluatePharma, Orphan Drug Market Data. [2022].
- Market Reports on Achondroplasia and Rare Disease Therapies. [2022].
- Industry Analysis on Rare Disease Drug Pricing and Reimbursement Trends. [2022].
Note: All projections and analyses are based on publicly available data as of early 2023, with ongoing market changes expected.
More… ↓
